Patents Assigned to Medigene AG
-
Patent number: 11267847Abstract: The present invention relates to nucleic acids encoding the novel parvoviral protein “assembly activating protein” (AAP), the encoded polypeptides, methods of producing the polypeptides, antibodies specific for AAP, the use of the nucleic acids for the preparation of the polypeptides, the use of the nucleic acids or the polypeptides for the preparation of the parvoviral particle and methods of producing parvoviral particles essentially consisting of VP3 by providing in addition to the coding sequence of the parvoviral structural protein VP3 a sequence fragment Z/a nucleic acid encoding AAP in the cell and expressing VP3 and fragment Z under control of a rep-independent promoter. Furthermore, the present invention relates to parvoviral particles essentially consisting of VP3 and/or obtainable by the above method as well as expression cassettes comprising (i) a heterologous promoter and (ii) VP3 coding sequence and/or fragment Z.Type: GrantFiled: May 17, 2019Date of Patent: March 8, 2022Assignees: Medigene AG, Deutsches KrebsforschungszentrumInventors: Florian Sonntag, Juergen Kleinschmidt, Markus Hoerer, Kerstin Pino Tossi
-
Patent number: 10822378Abstract: The present invention is related to a structural protein of a parvovirus with an amino acid insertion at the insertion site I-453, a library comprising the protein, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a vector, virus or cell comprising the nucleic acid, a process for the preparation of the protein, a medicament comprising the protein, nucleic acid or multimeric structure as well as methods and uses involving the protein, nucleic acid or multimeric structure.Type: GrantFiled: April 10, 2017Date of Patent: November 3, 2020Assignees: Medigene AG, Ludwig-Maximilians-Universitaet, Universitaet zu KoelnInventors: Kerstin Lux, Hildegard Buening, John Nieland, Jorge Boucas, Mirko Ritter, Markus Hoerer, Luca Perabo, Michael Hallek
-
Patent number: 10408834Abstract: The present invention is related to a method for identifying a parvovirus mutated structural protein capable of specifically binding to a binder for an antigen, a parvovirus mutated structural protein which comprises at least one B-cell epitope heterologous to the parvovirus, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a virus or cell comprising the protein, a method of preparing the protein, a medicament comprising the protein, nucleic acid or multimeric structure and its use.Type: GrantFiled: November 2, 2015Date of Patent: September 10, 2019Assignees: Medigene AG, Ludwig-Maximilians-Universitaet, Universitaet zu KoelnInventors: Hildegard Buening, John Nieland, Luca Perabo, Daniela Kuehn, Kerstin Pinotossi, Michael Hallek, Markus Hoerer, Mirko Ritter
-
Patent number: 10344057Abstract: The present invention relates to nucleic acids encoding the novel parvoviral protein “assembly activating protein” (AAP), the encoded polypeptides, methods of producing the polypeptides, antibodies specific for AAP, the use of the nucleic acids for the preparation of the polypeptides, the use of the nucleic acids or the polypeptides for the preparation of the parvoviral particle and methods of producing parvoviral particles essentially consisting of VP3 by providing in addition to the coding sequence of the parvoviral structural protein VP3 a sequence fragment Z/a nucleic acid encoding AAP in the cell and expressing VP3 and fragment Z under control of a rep-independent promoter. Furthermore, the present invention relates to parvoviral particles essentially consisting of VP3 and/oror obtainable by the above method as well as expression cassettes comprising (i) a heterologous promoter and (ii) VP3 coding sequence and/oror fragment Z.Type: GrantFiled: September 12, 2016Date of Patent: July 9, 2019Assignees: Deutsches Krebsforschungszentrum, Medigene AGInventors: Florian Sonntag, Juergen Kleinschmidt, Markus Hoerer, Kerstin Pino Tossi
-
Publication number: 20180066024Abstract: The present invention is related to a structural protein of a parvovirus with an amino acid insertion at the insertion site I-453, a library comprising the protein, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a vector, virus or cell comprising the nucleic acid, a process for the preparation of the protein, a medicament comprising the protein, nucleic acid or multimeric structure as well as methods and uses involving the protein, nucleic acid or multimeric structure.Type: ApplicationFiled: April 10, 2017Publication date: March 8, 2018Applicants: Medigene AG, Ludwig-Maximilians-Universitaet, Universitaet zu KoelnInventors: Kerstin LUX, Hildegard BUENING, John NIELAND, Jorge BOUCAS, Mirko RITTER, Markus HOERER, Luca PERABO, Michael HALLEK
-
Patent number: 9821043Abstract: The present invention relates to parvovirus mutated structural proteins comprising insertions of mimotopes of a HER2, compositions, multimeric structures, medicaments and vaccines comprising the same, nucleic acids, expression cassettes, constructs, vectors and cells comprising the nucleic acids, methods of preparing the structural proteins and methods of inducing a B-cell response or of treating a HER2-related disease.Type: GrantFiled: September 14, 2012Date of Patent: November 21, 2017Assignee: Medigene AGInventors: Uwe Michaelis, Erika Jensen-Jarolim, Christoph Rehfuess, Margit Weghofer
-
Patent number: 9770406Abstract: The invention relates to a medicament containing a compound of general formula (I), where R1=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C11-C21 alkyl, alkylene or alkinyl group, preferably a C11-C15 alkyl, alkylene or alkinyl group, particularly a C11-C13 alkyl, alkylene or alkinyl group, most preferably a C13 alkyl group, R2=independently, a straight or branched C1-C8 alkyl, alkylene or alkinyl group, preferably a C1-C6 alkyl, alkylene or alkinyl group, in particular a C2-C4 alkyl, alkylene or alkinyl group, most preferably a C3 alkyl group, a —[CH2—(CH2)m-O]nH group with n=1 to 10, preferably n=1 to 5, to m=1 to 5, preferably m=1 to 3, a —CH2—[CH—(OH)]p[CH2—R3]- group, where R3=independently H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/orType: GrantFiled: September 21, 2010Date of Patent: September 26, 2017Assignee: Medigene AGInventors: Yunik Chang, Robert Lathrop, Erwin Böhm, Irene Gander-Meisterernst, Regina Greger, Johanna Holldack, Ulrich Moebius
-
Patent number: 9624274Abstract: The present invention is related to a structural protein of a parvovirus with an amino acid insertion at the insertion site I-453, a library comprising the protein, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a vector, virus, or cell comprising the nucleic acid, a process for the preparation of the protein, a medicament comprising the protein, nucleic acid, or multimeric structure as well as methods and uses involving the protein, nucleic acid, or multimeric structure.Type: GrantFiled: October 11, 2012Date of Patent: April 18, 2017Assignees: Medigene AG, Ludwig-Maximilians-Universitaet, Universitaet zu KoelnInventors: Kerstin Lux, Hildegard Buening, John Nieland, Jorge Boucas, Mirko Ritter, Markus Hoerer, Luca Perabo, Michael Hallek
-
Patent number: 9464119Abstract: The present invention relates to nucleic acids encoding the novel parvoviral protein “assembly activating protein” (AAP), the encoded polypeptides, methods of producing the polypeptides, antibodies specific for AAP, the use of the nucleic acids for the preparation of the polypeptides, the use of the nucleic acids or the polypeptides for the preparation of the parvoviral particle and methods of producing parvoviral particles essentially consisting of VP3. Furthermore, the invention relates to parvoviral particles essentially consisting of VP3 and/or obtainable by the above method as well as expression cassettes comprising (i) a heterologous promoter and (ii) VP3 coding sequence and/or fragment Z. The invention further relates to a medicament, particularly a vaccine, comprising the parvoviral particles or expression cassettes and their use.Type: GrantFiled: March 4, 2010Date of Patent: October 11, 2016Assignees: Deutsches Krebsforschungszentrum, Medigene AGInventors: Florian Sonntag, Juergen Kleinschmidt, Markus Hoerer, Kerstin Lux
-
Patent number: 9260521Abstract: The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.Type: GrantFiled: October 3, 2013Date of Patent: February 16, 2016Assignees: MEDIGENE AG, DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFUNG DES OFFENTLICHEN RECHTSInventors: Daniela Kelm, Peter Altevogt, Gerhard Moldenhauer, Frank Breitling, Achim Krueger, Silke Baerreiter, Sandra Luettgau, Ulrich Moebius, Yi Li, Susanne Sebens, Heiner Schaefer
-
Patent number: 9238021Abstract: A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed.Type: GrantFiled: January 24, 2014Date of Patent: January 19, 2016Assignee: Medigene AGInventors: Carsten Mundus, Christian Welz, Oliver Schramel, Heinrich Haas, Thomas Fichert, Brita Schulze, Toralf Peymann, Uwe Michaelis, Michael Teifel, Friedrich Gruber, Gerhard Winter
-
Patent number: 9233094Abstract: The present invention relates to the use of pharmaceutical preparations comprising paclitaxel for administration to a human patient in need thereof.Type: GrantFiled: May 4, 2006Date of Patent: January 12, 2016Assignee: Medigene AGInventors: Axel Mescheder, Matthias Karrasch
-
Patent number: 9144563Abstract: The present invention relates to the use of a liposomal preparation for the manufacture of a pharmaceutical composition and the use of such a composition for the treatment of “triple receptor negative” breast cancer.Type: GrantFiled: March 26, 2012Date of Patent: September 29, 2015Assignee: Medigene AGInventors: Kay-Oliver Kliche, Axel Mescheder, Martine Piccart
-
Patent number: 9060998Abstract: The present invention refers to a method for treating cancerous or precancerous lesions of the skin by administering a pharmaceutically effective amount of a polyphenol to a patient as well as to the production of a medicament thereto.Type: GrantFiled: May 7, 2013Date of Patent: June 23, 2015Assignee: Medigene AGInventor: Eggert Stockfleth
-
Publication number: 20140205657Abstract: A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed.Type: ApplicationFiled: January 24, 2014Publication date: July 24, 2014Applicant: MEDIGENE AGInventors: Carsten MUNDUS, Christian WELZ, Oliver SCHRAMEL, Heinrich HAAS, Thomas FICHERT, Brita SCHULZE, Toralf PEYMANN, Uwe MICHAELIS, Michael TEIFEL, Friedrich GRUBER, Gerhard WINTER
-
Publication number: 20140120117Abstract: The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.Type: ApplicationFiled: October 3, 2013Publication date: May 1, 2014Applicants: MediGene AG, Deutsches Krebsforschungszentrum Stiftung des Oeffentlichen RechtsInventors: Daniela Kelm, Peter Altevogt, Gerhard Moldenhauer, Frank Breitling, Achim Krueger, Silke Baerreiter, Sandra Luettgau, Ulrich Moebius, Yi Li, Susanne Sebens, Heiner Schaefer
-
Patent number: 8663606Abstract: A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed.Type: GrantFiled: October 21, 2011Date of Patent: March 4, 2014Assignee: Medigene AGInventors: Carsten Mundus, Christian Welz, Oliver Schramel, Heinrich Haas, Thomas Fichert, Brita Schulze, Toralf Peymann, Uwe Michaelis, Michael Teifel, Friedrich Gruber, Gerhard Winter
-
Patent number: 8580258Abstract: The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.Type: GrantFiled: February 6, 2012Date of Patent: November 12, 2013Assignees: Deutsches krebsforschungszentrum Stiftung des Offentlichen Rechts, Medigene AGInventors: Daniela Kelm, Peter Altevogt, Gerhard Moldenhauer, Frank Brietling, Achim Krueger, Silke Wolterink, Sandra Luettgau, Ulrich Moebius, Yi Li, Susanne Sebens, Heiner Schaefer
-
Publication number: 20130259922Abstract: The present invention relates to the preparation of liposomes with enhanced loading capacity for pharmaceutically and/or diagnostically active agents and/or cosmetic agents which are substantially solubilized by the liposomal membranes, to liposome dispersions with enhanced stability with respect to release of the active agent and/or cosmetic agent from the liposomes obtainable by the process, and to pharmaceutical or cosmetic compositions comprising said stabilized liposome dispersions. The preparation may involve dehydration and rehydration steps of liposome dispersions which may be carried out by spray drying.Type: ApplicationFiled: May 20, 2011Publication date: October 3, 2013Applicant: MEDIGENE AGInventors: Heinrich Haas, Ursula Fattler
-
Publication number: 20130245113Abstract: The present invention refers to a method for treating cancerous or precancerous lesions of the skin by administering a pharmaceutically effective amount of a polyphenol to a patient as well as to the production of a medicament thereto.Type: ApplicationFiled: May 7, 2013Publication date: September 19, 2013Applicant: MediGene AGInventor: Eggert STOCKFLETH